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Abstract Central nervous system (CNS) infection is a near-
ly universal facet of systemic HIV infection that varies in
character and neurological consequences. While clinical
staging and neuropsychological test performance have been
helpful in evaluating patients, cerebrospinal fluid (CSF)
biomarkers present a valuable and objective approach to
more accurate diagnosis, assessment of treatment effects
and understanding of evolving pathobiology. We review
some lessons from our recent experience with CSF biomark-
er studies. We have used two approaches to biomarker anal-
ysis: targeted, hypothesis-driven and non-targeted explorato-
ry discovery methods. We illustrate the first with data from a
cross-sectional study of defined subject groups across the
spectrum of systemic and CNS disease progression and the
second with a longitudinal study of the CSF proteome in
subjects initiating antiretroviral treatment. Both approaches
can be useful and, indeed, complementary. The first is help-
ful in assessing known or hypothesized biomarkers while the
second can identify novel biomarkers and point to broad
interactions in pathogenesis. Common to both is the need for
well-defined samples and subjects that span a spectrum of
biological activity and biomarker concentrations. Previously-
defined guide biomarkers of CNS infection, inflammation and
neural injury are useful in categorizing samples for analysis
and providing critical biological context for biomarker dis-
covery studies. CSF biomarkers represent an underutilized but
valuable approach to understanding the interactions of HIV
and the CNS and to more objective diagnosis and assessment
of disease activity. Both hypothesis-based and discovery
methods can be useful in advancing the definition and use of
these biomarkers.
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Introduction
Infection of the central nervous system (CNS) begins during
primary systemic infection and continues throughout its
untreated course (Ellis et al. 1997; McArthur et al. 1997;
Gisslen et al. 1999; Spudich et al. 2005b; Valcour et al.
2012). While seemingly innocent over much of this course
and indeed clinically silent despite detectable HIV RNA and
an inflammatory response in the cerebrospinal fluid (CSF),
this infection may nevertheless impact brain function. Most
notably, in some patients CNS infection evolves into a more
invasive encephalitic form that presents clinically as HIV-
associated dementia (HAD) (Navia et al. 1986; Price et al.
1988). The detailed characteristics and pathogenesis of this
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shift from ‘benign’ meningitis to devastating encephalitis
remain poorly defined, though changes in both the viral
pathogen and host immune responses likely contribute in
concert (Schnell et al. 2011; Arrildt et al. 2012). Fortunately,
HAD can now be largely prevented by combination antire-
troviral therapy (ART), and as a result its incidence has
diminished markedly in the developed world where ART is
widely available (d’Arminio Monforte et al. 2004; Bhaskaran
et al. 2008; Lescure et al. 2011). In these regions HAD now
manifests almost exclusively in late presenters with advanced
immunodeficiency. Additionally, ART can arrest progression
and variably reverse the neurological dysfunction of HAD
(Sidtis et al. 1993; Tozzi et al. 1999).
However, despite this success, a number of recent reports
have documented impairment of neuropsychological testing
performance in treated patients, with or without clear symp-
toms, and have suggested that milder, though still important,
forms of neurological dysfunction in HIV patients remain
common even in the face of systemic viral suppression
(Tozzi et al. 2007; Heaton et al. 2010, 2011; Simioni et al.
2010; Smurzynski et al. 2011). These observations not only
challenge the effectiveness of current therapies in preventing
and treating CNS HIV infection and related CNS injury, but
point to the difficulty in defining the nature and activity of
the underlying disease processes using available clinical
evaluation methods. Disease definitions rely chiefly on stag-
ing severity (Price and Brew 1988; 1991) and particularly on
the extent of ‘impairment’ in neuropsychological test perfor-
mance (Antinori et al. 2007). These definitions do not direct-
ly take into account either the cause (beyond the context of
HIV infection) or the ongoing state of disease activity. This
can present a particular problem in the treated patient in
whom it is important to distinguish the cumulative effects
of past CNS damage from the impact of ongoing injury.
The nearly universal presence of HIV in CSF whether or
not overt CNS disease is present, the imprecision of pheno-
typic disease recognition even when extended to more quan-
titative measures by neuropsychological test biometrics, and
the frequency of confounding background conditions all call
for better objective assessments of infection and disease.
These pathogenetic and clinical needs, in turn, point to the
potential utility of objective, laboratory-based biomarkers in
overcoming the shortcomings of purely clinical definitions
of HIV-related CNS injury (Price et al. 2007).
While several types of biomarkers might help to address
these issues, CSF biomarkers are likely to be among the most
useful and are therefore the focus of this review which draws
on our recent experience in biomarker evaluation and dis-
covery. It describes some of the lessons we have learned in
the process of these studies. After a brief introduction de-
scribing a disease framework that organizes our approach,
we discuss the rationale for focusing on CSF and the poten-
tial applications of biomarkers that justify this attention. We
then describe examples of two different approaches to CSF
biomarkers, one hypothesis-driven and the other untargeted
and exploratory.
Disease framework for approaching CSF biomarkers
Figure 1 presents a simplified framework for classification of
biomarkers of CNS HIV infection and disease in relation to
their systemic counterparts. The top of the figure diagrams
the systemic interaction of HIVand the host immune system:
infection evolves over time with selection and expansion of
viral populations in concert with changes in the immune
system that exhibits both progressive deficiency and broad
activation (Hunt 2012). These interactions eventually lead to
an array of systemic diseases, including some more directly
related to the virus (e.g., HIV-related nephropathy), but more
frequently to opportunistic infections secondary to immuno-
deficiency, including those that define AIDS (http://www.
aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-oi-
prevention-and-treatment-guidelines/0). Immune activation
is critical to general systemic progression and also contrib-
utes to organ injuries from a variety of ‘nonAIDS-related’
diseases (El-Sadr et al. 2006, 2008; Phillips et al. 2008).
Importantly, these systemic interactions can be monitored
using blood biomarkers of these two disease components.
Thus, magnitude of systemic infection is followed by mea-
suring plasma HIV RNA levels that helps in predicting the
rate of disease progression, while the blood CD4+ T cell
count provides an index of the cumulative damage to the
immune system and the vulnerability to opportunistic dis-
eases (Mellors et al. 1997). Additional soluble and lympho-
cyte phenotype markers can also assess systemic immune
activation and predict disease progression (Lyles et al. 1999;
Giorgi et al. 2002; Neaton et al. 2010). These biomarkers
have had a profound effect on the advances in clinical man-
agement and therapeutics of HIV infection; indeed, it is
difficult to imagine the remarkable progress in this condition
without these biomarker tools in both clinical trials and
individual patient management. While more difficult to eval-
uate, CSF biomarkers have the potential for similar impact
on management of CNS HIV infection and resultant disease.
As indicated by the vertical arrows crossing the dotted
line representing the blood–brain and blood-CSF barriers in
Fig. 1, CNS HIV infection and local immune-inflammatory
responses originate with selective transfer from the blood
into the CNS of both infection (including both infected cells
and major cell targets) and systemic immune reactions. Sub-
sequently, local infection and immune-inflammatory reac-
tions can evolve further and impact nervous system function
and integrity, thus forming a pathogenic triangle with two
main interacting agonists and a target. CSF biomarkers can
assess each of these three disease components in order to
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characterize their evolution in particular disease states and
within individual patients.
We have selected a representative from each of these
components as CSF guide biomarkers to incorporate into
each of our studies: CSF HIV RNA, neopterin and neurofil-
ament light chain (NFL) concentrations. These serve as
indicators or vectors of these pathogenetic components; oth-
er terms that have been used for these types of biomarkers are
orthogonal biomarkers and endophenotypes (Cruchaga et al.
2010; Angel et al. 2012). Table 1 lists these three biomarkers
along with other examples from our own previous and on-
going work. Blood-brain barrier and endothelial injury might
be separately classified, but for simplicity they have been
included in the immune-inflammatory group.
Potentially informative CSF viral biomarkers include not
only the concentration of HIV RNA using the same clinical
methods applied to plasma, but also measurements of other
features of the virus including the genetic relationship of
CSF viral populations to those of plasma and differences in
drug resistance, cell tropism and receptor usage between
these two compartments (Spudich et al. 2005a; Schnell
et al. 2010). At some future time, the list might also include
more direct markers of neuropathogenicity, though beyond
macrophage-tropism these have proved elusive (Dunfee
et al. 2006). While the diagnostic value of CSF HIV RNA
measurement is limited by detection in nearly all untreated
individuals, the presence of virus and its drug resistance profile
provides evidence and characterization of an active viral target.
This evidence is essential to implicating CNS HIV infection as
a possible cause of CNS disease and especially important in
treated patients with neurosymptomatic viral escape (Canestri
et al. 2010; Peluso et al. 2012) but perhaps also in other patients
that harbor CNS resistance profiles different from those of
plasma virus.
Biomarkers of immune and inflammatory responses in-
clude both soluble and cell-based markers. We have used
neopterin, a pteridine biomarker metabolite that is readily
measured in CSF (Hagberg et al. 2010), as our cardinal guide
marker in this category (Angel et al. 2012). It is produced by
cells of the monocyte-macrophage lineage and likely also by
astrocytes (Cano et al. 2008) within the CNS compartment,
reflects primarily stimulation by interferon gamma, and in-
creases as systemic HIV infection progresses with highest
levels in HAD (Fig. 2) and CNS opportunistic infections
(Hagberg et al. 2010). Other soluble biomarkers include a
range of cytokines, chemokines, markers of cell activation
and blood-brain barrier dysfunction, a sample of which is
listed in Table 1. CSF can also be used for cell-based assess-
ment of T-cell and monocyte phenotypes related to activa-
tion, maturation and cell trafficking, though such studies are
















Fig. 1 Schematic diagram of salient systemic and CNS HIV disease
components. CNS HIV infection and immune responses initially are
extensions across the blood–brain and blood-CSF barriers (horizontal
dashed line) of their systemic counterparts, though with variable selec-
tion and local evolution depending on the stages of disease. Within the
nervous system, both the virus and immune responses may impact the
CNS and its function in the depicted triangle. In the small font are
examples of biomarkers for each of the main pathogenic components.
Plasma HIV RNA and blood CD4 cells in systemic disease have proved
to be essential biomarkers in systemic management, while CSF HIV
RNA, neopterin and NFL have served as principal guide biomarkers in
our studies of CNS infection and injury











Immune Neopterin CCL2 (MCP-1), CXCL10 (IP-10),
β2M, TNFα, sCD14, sCD163,
sVCAM-1, MMP-9, TIMP-1;
T-cell & monocyte cell
activation, maturation,
traffic phenotypes
Neural NFL t-tau, p-tau, Aβ1-42, sAPPα, sAPPβ
CCL2 (MCP-1, monocyte chemokine protein 1) a CSF marker for HIV
and SIVencephalitis (Cinque et al. 1998; Kelder et al. 1998; Mankowski
et al. 2004); CXCL10 (IP-10, interferon protein 10) likely the main
chemokine for CSF lymphocytes (Cinque et al. 2005); beta-2-
microglobulin (β2M), component of the MHC-I complex increased in
CSF in HAD (Brew et al. 1992); TNFα (tumor necrosis factor alpha) also
increased in the CSF in HAD (Mastroianni et al. 1990; Nolting et al.
2009); sCD14, the soluble LPS ligand increased in the CSF in HIV
(Kamat et al. 2012); sCD163, a macrophage chemokine increased in
blood in HIV (Kamat et al. 2012); sVCAM (soluble vascular adhesion
molecule 1) mediates lymphocye and monocyte adhesion to vascular
endothelium; MMP-9 (matrix metallopeptidase 9) and TIMP-1 (tissue
inhibitor of metalloproteinases one) are involved in integrity of the
extracellular matrix. T-tau (total tau) and p-tau (phosphorolated tau) are
different states of the neuronal tau protein that are elevated in CSF in
Alzheimer’s disease while amyloid beta 1–42 (Aβ1-42) is an amyloid
cleavage product depressed in the CSF of Alzheimer’s disease (Blennow
et al. 2010); sAPPα, sAPPβ are soluble degradation products of the
amyloid precursor protein that are reduced in CSF in HAD (Gisslen
et al. 2009)
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time assay, since CSF cells are fragile in storage (Ho et al.
2013). Since inflammatory responses and immunopathology
are thought to be important in HIV neuropathology, markers
in this class provide diagnostic evidence that disease is
associated with inflammation (and thus plausibly caused by
HIV) and may be helpful in following the effects of therapy
(Yilmaz et al. 2013) Low-level residual elevation of CSF
neopterin in treated patients also suggests that suppressive
treatment does not always fully restore the normal CNS
immunological milieu, though this low-level elevation of
neopterin and other inflammatory biomarkers has not yet
been clearly correlated with neurological progression
(Gisslen et al. 2007b; Eden et al. 2010; Hagberg et al.
2010). Further delineation of the profile of inflammatory
changes should provide further understanding of this central
aspect of neuropathogenesis.
A number of neural biomarkers have been studied. We use
NFL as a guide biomarker in this category (Abdulle et al.
2007), based on its sensitivity in detecting ongoing CNS
injury in this setting, particularly when using the newer,
more sensitive version of the assay available commercially
(Krut et al. 2013; Peluso et al. 2013). Other neural markers
that we and others have assessed are listed in Table 1 and
include indicators of disturbed amyloid and tau metabolism
(Clifford et al. 2009; Gisslen et al. 2009). Though not as
sensitive as NFL, these biomarkers may be helpful in
distinguishing HAD from Alzheimer’s disease. While none
of these neural biomarkers are specific for HIV neuropathol-
ogy, they importantly indicate active CNS injury in this
setting (Gisslen et al. 2009). Glial markers can also be
assessed, though they have not generally been found as
useful (Andersson et al. 1998; Pemberton and Brew 2001).
While this discussion has focused on biomarker use in
detecting or characterizing HIV-related CNS injury and omits
consideration of biomarkers related to other neuropathogens
(including particularly those causing opportunistic infections
such as JC virus nucleic acid in progressive multifocal
leukoencephalopathy or cryptococcal antigen in meningitis),
it is important to emphasize the value of this class of diagnostic
markers in neurological disease complicating HIV infection
(Cinque et al. 2007). However, detailed discussion of these
biomarkers is simply beyond the scope of this review.
Choice of CSF as source of biomarkers and its limitations
Before more directly considering approaches to these mea-
surements, it is appropriate to ask: Why focus on CSF? The
main rationale for this rests on: 1) CSF’s proximity to the
brain and spinal cord with which it exchanges molecular
components, and thus allows sampling of the brain microen-
vironment (Yilmaz et al. 2012); and 2) its ready availability
for sampling, including repeated sampling for longitudinal
observation, with low morbidity (de Almeida et al. 2011).
Importantly, while CNS HIV infection originates with viral
and immune components of systemic infection transposed
into the CNS, infection is variably ‘compartmentalized’ and
features viral and immune components that are not clearly
reflected in blood. Thus, the same measurements in CSF and
blood may be dominated by disconnected or independent















































































































































Fig. 2 Changes in the three guide markers with disease progression and
suppressive treatment studied cross-sectionally. The panels show the
changes in CSF HIV RNA, neopterin and NFL with infection as
systemic disease progresses, showing HIV uninfected controls (HIV-),
neuroasymptomatic (NA) subjects with progressively lower blood
CD4+ T cells, patients with HAD, and a group on suppressive therapy
(N=20 in each group except HAD with 12 and suppressed with 19).
CSF HIV RNA was elevated in all untreated groups, and highest in
HAD though in this small study only the treated-suppressed differed
from the other infected groups (P<0.05–<0.001). CSF neopterin was
elevated in all the untreated HIV subjects, though highest in the HAD
group (all HIV-infected groups differed from HIV- except CD4>350;
HAD differed from suppressed and CD4>350; suppressed differed
from all untreated except CD4 >350) (p values). NFL was highest in
the HIV group (above normal in all) but NA subjects with lower CD4+
T cells showed a substantial prevalence of elevated levels indicative of
subclinical CNS injury (HAD, CD4 <50 and 50–199 differed from
HIV- while HAD differed from all groups except CD4 <50) (stat p
values). Statistical comparison used Kruskal-Wallis test and Dunn’s
post hoc test of multiple comparisons; graph and statistics prepared on
Prism 6 (Graphpad Software Inc, San Diego, CA). Box plots show
median and intraquartile range, ‘+’ shows mean and error bars
the 10–90 percentiles
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processes, and blood will not provide direct information
about events within the nervous system.
Similarly, blood sampling would be a far more convenient
approach to analysis of brain-derived neural biomarkers, but
the obscuration, dilution or degradation of CNS metabolic
traces in the blood have largely prevented blood from pro-
viding useful or direct information about brain pathobiology
in HIV. This is, of course, also a major issue in other neuro-
degenerative diseases for which efforts are underway to
develop sensitive assays that can measure informative mol-
ecules ‘spilling over’ from brain to blood. This has only
yielded limited success thus far, particularly compared to
the relative ease of such measurements in CSF (Blennow
et al. 2010).
It is also pertinent to emphasize some of the biolog-
ical pitfalls of interpreting CSF findings in HIV infec-
tion, particularly with regard to HIV and immune bio-
markers. This relates to the mixed origin of these mol-
ecules within the CNS independent of systemic processes.
Thus, CSF measurements may reflect processes localized
within the leptomeninges, on the one hand, or within the brain
and spinal cord parenchyma and associated perivascular
spaces, on the other. Both of these anatomical CNS compo-
nents are compartmentalized from blood and indeed they
share constituents by diffusion. They may also be subject to
parallel disease processes, including HIV infection and in-
flammation. However, they also may contribute differently
to CSF sampled by lumbar puncture in different settings. At
the extremes of evolving CNS HIV infection, CSF sampling
can reflect predominantly meningeal or encephalitic infec-
tions, the first a nearly universal facet of untreated chronic
infection and the second a late complication manifesting clin-
ically as HAD. For this reason, interpretation of HIV and
immune biomarkers must always ask whether a measured
analyte derives from one or the other of these spaces (or even
more directly, from blood). This is particularly at issue with
viral and inflammatory biomarkers and less so with neural
biomarkers that originate in the brain and not meninges,
though spinal nerve roots may also potentially ‘contaminate’
CSF with neuronal breakdown products in the presence of
neuropathies.
This distinction of compartment origin may be critical to
interpretation. For example, HIV RNA can be measured in
the CSF of nearly all untreated patients with detectable
plasma viral loads, dating from the earliest sampling during
acute infection through the chronic phase and in the presence
of HAD with underlying HIVE (Ellis et al. 1997; McArthur
et al. 1997; Spudich et al. 2005b, 2011; Valcour et al. 2012).
Even in treated patients with plasma suppression, HIV RNA
can be detected in CSF at very low levels using high fluid
volumes and sensitive methods such as the single copy assay,
though not as commonly as detection of such ‘residual’ virus
in plasma (Dahl et al. 2011). This distinguishes detection of
HIV RNA from most other meningitides or encephalidites in
which detection of a virus in CSF proves CNS disease
etiology (for example detection of CSF JC virus DNA in
progressive multifocal leukoencephalopathy (Cinque et al.
2007). In HIV infection, the origin of virus detected in CSF
changes across the spectrum of infection. In early infection
the CSF HIV population is generally similar to that of blood
and likely reflects origin in the meninges, production by
trafficking CD4+ T cells and exhibiting T cell tropism
(Arrildt et al. 2012; Swanstrom and Coffin 2012). However,
it then becomes more compartmentalized, and this is partic-
ularly notable in HAD.While CSF virus populations in HAD
may be either T cell- or macrophage (M)-tropic, their com-
partmentalization and CNS origin is demonstrated by the
genetic distance from the blood population (Schnell et al.
2011). Because of these different viral sources, simply mea-
suring the overall CSF HIV RNA level does not clearly
indicate the origin or neuropathogenic effect.
The same difficulty can arise with some CSF immunolog-
ical markers that reflect either meningeal inflammation, like-
ly mainly originating or triggered by T cells, or parenchymal
immune activation involving principally macrophages and
related cells (Cinque et al. 1998; Hagberg et al. 2010; Burdo
et al. 2013). While the component processes in these two
spaces may diverge—potentially allowing dissection based
on cytokine profiles – they also likely share some features
that lead to overlap in some of the measured biomarkers,
reducing their diagnostic and pathogenetic specificity.
Applications of CSF biomarkers
There are two principal uses for CSF biomarkers: character-
izing clinical states and defining pathogenesis. Though the
same biomarkers may be used in both contexts, these objec-
tives are sufficiently distinct that approaches to discovery
and testing often differ.
Clinical applications
Because of the current difficulties in clinical diagnosis and
management of HIV-related CNS disease, CSF biomarkers
promise to integrate objective, laboratory-based information
into both clinical practice and clinical trials. Of particular
importance is the capacity to segregate active disease from
static injury with residual deficits. This is a crucial issue in
patient evaluations and, more particularly, for treatment deci-
sions. Both active and residual disease can present similar
symptoms and signs along with similar phenotypes and se-
verity of impairment on neuropsychological testing. However,
only active virus-driven injury presents a target for direct
intervention with initiation or modification of antiretroviral
therapy or adjunctive measures targeting downstream effects.
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By contrast, static disease results from past injury with resid-
ual deficits which, while still important, requires focus on
restorative efforts including rehabilitation and supportive
measures. This distinction is important, not only for the indi-
vidual patient in clinical practice, but in defining and evaluat-
ing subjects in clinical trials in which patients with static
disease can markedly reduce the effect size and power of
evaluating interventions designed to mitigate active HIV-
driven injury. Mislabeling of patients with inactive disease
also interferes with studies designed to characterize biological
features of presumed active disease and its correlates.
While longitudinal clinical observations can also be used
to distinguish active from static disease (and to validate the
biomarker definitions of active versus static injury), an ac-
curate longitudinal perspective is often difficult to obtain
during a single clinic visit or at the start of a clinical trial
where only a ‘snapshot’ is available. Biomarkers of active
CNS disease potentially can also be used as surrogate clinical
trial endpoints, much like plasma HIV RNA and blood
CD4+ T cells are used in studies of systemic disease treat-
ment. Obviously, these clinical applications require robust
and reproducible analytical methods and established refer-
ence standards. Hence, initial approaches as emphasized in
this review need to be followed by more rigorous validation
studies so that a pathogenetic biomarker can transition to a
valid clinical surrogate marker (Neaton et al. 2010).
Pathogenesis studies
CSF biomarkers can also provide important insight into path-
ogenesis, measuring component biological processes that are
not apparent either clinically or by other measurements, in-
cluding blood studies or neuroimaging. Studies of pathogen-
esis may also focus on several biomarkers simultaneously,
aiming to define not only their role in our association with
an aspect of disease production but also their interactions.
Hence, while clinical studies often strive for parsimony and
the value of one or only a few measures, pathogenesis studies
may look at a broader spectrum of biomarkers to understand
different components of disease. Both novel and established
biomarkers may provide insight into underlying mechanisms
and how these mechanisms relate to different stages or man-
ifestations of CNS HIV infection and resultant disease. Stud-
ies of pathogenesis may also seek to identify therapeutic
targets beyond virus replication, including ‘adjuvant’ strate-
gies that seek to mitigate components of pathogenesis other
than simple reduction in infection.
Approaches to biomarker evaluation
Approaches to biomarker studies can be classified on the
basis of a number of features. Here we review two different
approaches and illustrate these with two of our recent stud-
ies, one targeted and hypothesis-directed and the other using
an untargeted discovery design (Table 2).
Targeted biomarker evaluation
Our ongoing targeted, hypothesis-directed study is typical of
an approach in which candidate biomarkers are examined for
their possible clinical application (though also with a back-
ground interest in their pathogenetic implications). Bio-
markers included in this type of study are often selected on
the basis of blood biomarkers that might also be useful in
CSF, observations made in cell culture or animal studies, or
theoretical promise related to a particular facet of disease.
Using data extracted from this study, we illustrate results
measuring the three cardinal guide biomarkers listed earlier
(Fig. 2). HIV RNA (Mellors et al. 1997; Riddler and Mellors
1997; Egger et al. 2002) and neopterin (Mildvan et al. 2005)
were first used as blood biomarkers in HIV infection while
CSF NFL has been applied as a biomarker of CNS injury in a
variety of neurological conditions (Rosengren et al. 1996;
Gunnarsson et al. 2011; Bech et al. 2012; Peluso et al. 2013).
As shown in Fig. 2, we assessed these CSF biomarkers in
defined groups of patients representing phases of untreated
systemic disease progression (patients without overt neuro-
logical symptoms divided into four groups by blood CD4+ T
lymphocyte counts), a group with HAD, an antiretroviral
treated group with plasma and CSF suppression and an
HIV uninfected control group. The results shown here are
similar to those previously published related to larger inde-
pendent samples (Spudich et al. 2005b; Gisslen et al. 2007a;
Hagberg et al. 2010). They show a rise in CSF HIV RNA
with systemic progression, lower concentrations in patients
with <50 blood CD4+ cells per μL, and the highest level in
HAD. CSF neopterin was also elevated in all HIV-infected
patients, with highest in HAD and reduction in the treated
group, though perhaps not quite to HIV negative control
levels (Yilmaz et al. 2008; Hagberg et al. 2010). CSF NFL
showed the most distinct increase in HAD (elevated in all
patients) but the concentration of this neural biomarker was
also elevated in a substantial number of neuroasymptomatic
with reduced blood CD4+ T cells, indicating subclinical
neuro-axonal injury in these subjects (Gisslen et al. 2007a;
Mellgren et al. 2007). The CD4+ T cell divisions used to
define these groups not only have meaning with respect to
systemic disease state, they are helpful in examining evolu-
tion of the CSF biomarker concentrations with progressive
immunosuppression, and we are therefore using this subject-
grouping to explore other biomarkers, including the ones
listed in Table 1.
Because the biomarkers were defined at the initiation of
study, they address an articulated or implied hypothesis—the
association of the biomarker with a particular aspect of
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disease evolution. Typical of this type of study, it used a
cross-sectional, observational structure drawing on archived
samples from a relatively large number of subjects, though
not as large as other more definitive studies. The results
illustrate a number of important features of advancing dis-
ease as described in the legend of Fig. 2.
While the initial analytical approach compared the de-
fined subject groups, analysis can also be extended to exam-
ine interrelations among the measurements across the larger
subject sample. Analysis of one or a few novel biomarkers
using multiplex assays is relatively straightforward at this
exploratory level because of the circumscribed number of
variables examined. This type of cross-sectional design can
be supplemented by longitudinal studies to define the natural
history and progression or response to therapy of individual
subjects (Spudich et al. 2005b).
In undertaking these studies, we started with a simple
classification of HIV-infected individuals, separating those
with HAD from those without overt neurological symptoms
and signs, listed as neuroasymptomatics (NA). This strategy,
for the time being, ignores the important issue of using
biomarkers to define milder CNS disease in untreated and
treated subjects that has been classified under the Frascati
criteria as minor neurocognitive disorder (MND) and asymp-
tomatic neurocognitive impairment (ANI) defined by similar
impairment levels on formal neuropsychological testing
(Antinori et al. 2007). Along with HAD, these designations
define the three levels of HIV-associated neurocognitive
disorders (HAND).
In practice defining the biomarkers related to MND and
ANI conditions presents a formidable problem. These condi-
tions are etiologically and pathogenetically more heteroge-
neous and ambiguous (Heaton et al. 2011; Bonnet et al.
2013), and can be applied to patients with both active
neurodegeneration and static residual injury from past insults,
clearly different biological states. For this reason we, like
other groups, have begun to explore biomarkers by defining
HAD with the general idea that eventually one will be able to
use these findings to ‘work backwards’ in exploring their
application to the milder disease that is now of particular
interest in treated populations in the developed world.
Untargeted biomarker discovery
This illustrative second study was not limited by a priori hy-
potheses and used high-throughput proteomics, a discovery-
based approach to identify novel protein biomarkers and iden-
tify their possible relationships (Angel et al. 2012). This, the
first of our HIV CSF proteomic studies, used a different study
structure and analyzed CSF from a much smaller group of
subjects sampled longitudinally in the context of initiating
antiretroviral therapy. For this study, we viewed the initiation
of treatment as an ‘experimental’ intervention that rapidly and
profoundly altered the infection and its inflammatory
and neural consequences, leading to related changes in CSF
biomarker concentrations. For some subjects we also included
longitudinal observations of progressive untreated disease be-
fore treatment initiation. Part of the rationale for this approach
related to the potentially obscuring effects of within-subject
CSF proteome features that might not be relevant to the ques-
tion being addressed. We reasoned that a smaller number of
subjects with repeated sampling during a period treatment- or
disease-related biological perturbation, could reduce the im-
pact of these idiosyncratic subject effects, and, in fact, individ-
ual subjects did show distinctive features of the CSF proteome
through the course of sampling (Angel et al. 2012).
However, using this approach how does one then analyze
and interpret such a heterogeneous group of subjects with
different baseline states, variable timing of and responses to
ART and different number of samplings? For our initial
analysis we used the three cardinal biomarkers listed earlier
and examined how they correlated with features of the pro-
teome over the entire sample set. This allowed us to identify
proteins that varied in concentration with these markers, and
thus were associated with changes in infection, immune
activation-inflammation and neural injury as defined by the-
se guides, thereby providing important context for the mea-
sured changes in these identified proteins and an initial
description of their correlations and biological pathway re-
lations. We also more directly examined correlations among
the identified proteins themselves (Angel et al. 2012).
Among the differences in this type of discovery study and
the hypothesis-based study as described above, is that the
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large number of identified proteins present a formidable
informatics and analytical challenge. The use of the guide
biomarkers allows an initial view of the proteome that can
then be extended to an increasingly broad perspective by
building on these associations. Thus, these initially defined
endophenotypes serve as a scaffold for extended explora-
tions. Figure 3 shows an example of this from our proteomics
study, listing correlating proteins and pathway diagram in-
corporating several of these (Angel et al. 2012).
Cross-sectional design can also be used for pathogenetic
studies, and indeed the cross-sectional study described earlier
represents one phase of a broader study that began with
definitions of guide biomarkers, has been extending to addi-
tional predefined biomarkers, and is now being further ex-
tended through proteomic analysis. In this study, differences
in the proteome between groups and across the entire sample
can be analyzed in relation to these defined guide biomarkers.
Once this type of study reveals a series of pathogenetically
interesting proteins, the challenges then include: ‘validating’
the general findings using more quantitative assays, most
often immunoassays, applied to some of the salient proteins;
reproducing the salient findings independently using an inde-
pendent sample set or experimental paradigm; and finally
beginning to explore causality in the various relationships
suggested by the correlations and pathways. In this sense, this
type of exploratory methodology is only the beginning of
pathogenetic exploration, but nonetheless invaluable. Similar-
ly, identified proteins that appear attractive as clinical bio-
markers need to be characterized further using simpler, more
quantitative and eventually reproducible assay methods that
can be broadly applied in clinical settings.
Classification of subjects and samples
Whatever approach is taken to characterize CSF biomarkers in
HIV infection, a critical requirement is the careful and clear
classification of study subjects and samples. This is a common
feature of both hypothesis-driven and discovery methods.
There is more than one structural approach to this issue. This
includes the use of biologically meaningful, well-defined




























Fig. 3 Protein correlations with CSF neopterin and pathway diagram. The
heat map on the left-side diagrams the significant protein correlations
(proteins with R values either >0.3 or<−0.3 by Spearman analysis) with
decreasing concentrations of CSF neopterin. The upper nine rows show
normalized (Z scores) protein concentration groups with positive correla-
tions (green to red) while those below show negative correlations (red to
green). The right diagram shows results of a pathway analysis that
included the highest number of previously defined relationships of these
neopterin correlating proteins and identified APP (amyloid precursor
protein) as a ‘node’ in these relationships using Ingenuity Pathway Anal-
ysis (http://www.ingenuity.com/). Thus, using neopterin as an external
biomarker we were able to identify an unrelated CSF neuronal protein
that had previously shown to correlate with HAD, thus validating this
overall approachwith respect. The pathway analysis also suggests possible
links in the pathogenesis related to these protein changes, based on
previously reported interactions of the correlating proteins. Abbreviations
use standard nomenclature. Undefined abbreviations on right panel in-
clude: APP amyloid precursor protein; CD14 cluster of differentiation 14,
also monocyte differentiation antigen that serves as lipopolysaccharide
(LPS) co-receptor. Data are fromAngel et al. (Angel et al. 2012) where the
findings are described in greater detail
1154 J Neuroimmune Pharmacol (2013) 8:1147–1158
with the subject divisions across the spectrum of systemic
progression, transition to HAD and treatment. Longitudinal
studies may also rely on patient classifications, but also can
benefit from a defined structure that includes similar baseline
characteristics, interventions and scheduled assessments that
allow subject or time groupings for analysis. The second
approach, using independent biomarkers to classify samples,
is generally more flexible and can be used for either primary or
secondary analysis.
Figure 4 compares some of the sample features of the two
illustrated studies, examining the distributions of concentra-
tions of the guide biomarker. Both designs provided sample
sets that spanned a wide and biologically meaningful spec-
trum of concentrations for all three of the measurements.
This is an important aspect of sample selection since it
predicts a similar range for proteomic or other analyses and
for defining associations among the biomarkers. The differ-
ences in the sample sets are described in the figure legend. In
the cross-sectional study, the specimen spectrum was com-
posed of independent subjects presumably at a relatively
steady state at the time of sampling, since all were clinically
and virologically stable at sampling. In the longitudinal
study, a smaller group of subjects assume interdigitating
places across the spectrum of concentrations. Possible issues
with this second approach include the variable number of
samples for individual subjects and the dynamic state of the
patients at many of these points. On the other hand, this
dynamic state may be important for biomarker associations
as well in measuring their changes with treatment. The two
studies can be regarded as complementary in several aspects
and together should provide both a steady-state and dynamic
view of CSF biomarker changes.
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Fig. 4 Comparison of biomarker sample distributions of two studies. In
each panel the sample results have been sorted by value from highest to
lowest for the listed biomarkers. The top three panels show data from
the cross-sectional study outlined earlier and presented by group in
Fig. 2 using the same color scheme that is also defined in the middle
panel. The lower three panels show sorted samples from the longitudi-
nal study, with those from each individual subject now identified by
color as shown in the middle panel. The X axes differ because of the
larger number of samples in the cross-sectional study. The CSF HIV
RNA (left panels) shows a similar distribution in the two studies from
the level of quantitation (40 copies per mL) to >100,000 copies per mL.
Similarly, the CSF neopterin concentrations of both sample sets span a
similar distribution. The CSF NFL values in the two studies show
differences that relate to two factors. First, the assays differed in the
two studies with the cross-sectional study (actually performed more
recently) using the newer, more sensitive assay (Peluso et al. 2013)
accounting for both the higher values and the continued value spread at
the lower end of concentrations (including within the normal value
distribution below 890 ng per L), whereas in the second study the lower
half of the sample was below the detection limit of 125 ng/L) for the
older assay (Gisslen et al. 2007a). Second, the longitudinal study had a
larger number of samples from neurologically abnormal subjects as a
result of selection of HAD patients and those with low blood CD4+
cells for study. Overall, both studies show a continuous distribution of
values for each of the CSF biomarkers
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Conclusions
Despite the early recognition of the importance of CNS HIV
infection and its link to brain injury, diagnosis and manage-
ment has been limited by the lack of objective measures of
disease. While CSF biomarkers have already been useful in
defining the natural history of these linked processes and
their responses to treatment, they have been underexploited
for pathogenetic study and have found very limited use in the
clinic for either patient management or clinical trials. While
there is clear need for further characterization of already-
studied biomarkers and discovery of additional useful bio-
markers, it is also time to undertake studies that validate
available CSF biomarkers and open the way for their use in
clinical practice either as single markers or using a combi-
natorial approach (Gisslen et al. 2007b).
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